Latest news

• GSK beats expectations thanks to strong vaccine sales in Q2

  EMA). In Q2, GSK announced $16m in sales for its Vir Biotech-partnered COVID-19 antibody treatment sotrovimab – the company recently signed a deal with the European Commission to supply up

• EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy

  This includes Lilly’s bamlanivimab and etesevimab combination, Roche and Regeneron’s REGEN-COV (casirivimab and imdevimab), Celltrion’s regdanivimab and GlaxoSmithKline/Vir Biotech’s sotrovimab.

• GSK, Vir’s COVID-19 mAb scores FDA emergency use approval

  GlaxoSmithKline (GSK) and Vir Biotech’s COVID-19 monoclonal antibody (mAb) sotrovimab has been granted an emergency use authorisation (EUA) from the US Food and Drug Administration (FDA). ... The EUA clears sotrovimab – previously known as VIR-7831

• EMA concludes GSK, Vir’s mAb can be used to treat high-risk COVID-19 patients

  The European Medicines Agency (EMA) has issued advice for the use of GlaxoSmithKline (GSK) and Vir Biotech’s monoclonal antibody (mAb) VIR-7831 for the treatment of COVID-19. ... GSK and Vir also have a second mAb, VIR-7832, which is being investigated

• EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19

  and with other antibodies, including VIR-7831, versus placebo in low-risk adults with mild-to-moderate COVID-19. ... GSK and Vir have a second mAb, VIR-7832, which is also being investigated as a potential COVID-19 treatment.